PHARMACOKINETICS AND SAFETY OF A LONG-ACTING SUBCUTANEOUS FORMULATION OF 2-METHOXYESTRADIOL (2ME) IN HEALTHY VOLUNTEERS

被引：0
|
作者：
Tofovic, S. [1 ]
Jackson, E. [2 ,3 ]
Piche, C. [4 ]
机构：
[1] Univ Pittsburgh, Sch Med, Dept Med, Ctr Clin Pharmacol, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Dept Med & Pharmacol, Ctr Clin Pharmacol, Pittsburgh, PA USA
[3] Univ Pittsburgh, Sch Med, Dept Biol Chem, Ctr Clin Pharmacol, Pittsburgh, PA USA
[4] PR Pharmaceut, Ft Collins, CO USA
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2009年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [21] Safety Trials of Long-Acting β2-Agonists
    Weinberger, Miles
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (15): : 1481 - 1482
  • [22] Safety of long-acting β2-agonists in asthma
    de Benedictis, Fernando Maria
    Carloni, Ines
    THORAX, 2012, 67 (11) : 1014 - U110
  • [23] Safety in the use of long-acting β2 agonists in asthma
    Solnor, Ludvik Saxhaug
    Skeie, Oystein Stenerud
    Spigset, Olav
    Slordal, Lars
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2019, 139 (17) : 1666 - 1670
  • [24] Safety of long-acting β2-agonists in asthma
    Rishton, Louise
    LANCET RESPIRATORY MEDICINE, 2016, 4 (11): : 860 - 860
  • [25] Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization
    Robinson, MR
    Baffi, J
    Yuan, P
    Sung, C
    Byrnes, G
    Cox, TA
    Csaky, KG
    EXPERIMENTAL EYE RESEARCH, 2002, 74 (02) : 309 - 317
  • [26] PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF A LONG-ACTING FORMULATION OF THE NEW SOMATOSTATIN ANALOG, LANREOTIDE, IN NORMAL HEALTHY-VOLUNTEERS
    KUHN, JM
    LEGRAND, A
    RUIZ, JM
    OBACH, R
    DERONZAN, J
    THOMAS, F
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (03) : 213 - 219
  • [27] Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers
    Jucker, Beat M.
    Fuchs, Edward J.
    Lee, Sarah
    Damian, Valeriu
    Galette, Paul
    Janiczek, Robert
    Macura, Katarzyna J.
    Jacobs, Michael A.
    Weld, Ethel D.
    Solaiyappan, Meiyappan
    D'Amico, Ronald
    Shaik, Jafar Sadik
    Bakshi, Kalpana
    Han, Kelong
    Ford, Susan
    Margolis, David
    Spreen, William
    Gupta, Manish K.
    Hendrix, Craig W.
    Patel, Parul
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (04) : 1655 - 1666
  • [28] Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects
    Yi-Wen Huang
    Chan-Yen Tsai
    Chung-Wei Tsai
    William Wang
    Jingjing Zhang
    Albert Qin
    Chingleou Teng
    Bo Song
    Mei-xia Wang
    Advances in Therapy, 2021, 38 : 4756 - 4770
  • [29] Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects
    Huang, Yi-Wen
    Tsai, Chan-Yen
    Tsai, Chung-Wei
    Wang, William
    Zhang, Jingjing
    Qin, Albert
    Teng, Chingleou
    Song, Bo
    Wang, Mei-xia
    ADVANCES IN THERAPY, 2021, 38 (09) : 4756 - 4770
  • [30] Phase 1 open-label study assessing the pharmacokinetics and safety of TV-46000, a novel long-acting subcutaneous injectable formulation of risperidone
    Wagner, A. Merenlender
    Elgart, A.
    Perlstein, I.
    Lamson, M.
    Tiver, R.
    Kalmanczhelyi, A.
    Spiegelstein, O.
    Mackellar, A.
    Harary, E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S339 - S340
12345